Cediranib for metastatic alveolar soft part sarcoma - Wikidata - awgldk - TriplyDB

Cediranib for metastatic alveolar soft part sarcoma

Cediranib for metastatic alveolar soft part sarcoma

http://www.wikidata.org/entity/Q34651131

about

Pazopanib in the management of advanced soft tissue sarcomas Microenvironmental Targets in Sarcoma Treatment of Adult Soft Tissue Sarcomas: An Overview Modeling Alveolar Soft Part Sarcomagenesis in the Mouse: A Role for Lactate in the Tumor Microenvironment Advances and controversies in the management of soft tissue sarcomas.Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream® system.Identification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray.Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS).Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.Emerging therapies for adult soft tissue sarcoma.Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases Adult alveolar soft part sarcoma of the head and neck: a report of two cases and literature review Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines Conference report on the 28th annual meeting of the European Musculo-Skeletal Oncology Society, 29 April-1 May 2015, Athens Alveolar soft part sarcoma presenting as a breast metastasis in a patient with a history of thyroid cancer: a case report Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.Alveolar soft-part sarcoma in the left forearm with cardiac metastasis: A case report and literature review Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma Targeted therapy for soft tissue sarcomas in adolescents and young adults.New drugs in sarcomas.Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies.Soft tissue sarcomas, a look into the future: different treatments for different subtypes.The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.Molecular diagnostics in soft tissue sarcomas and gastrointestinal stromal tumors.Current and advancing systemic treatment options for soft tissue sarcomas.Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas.Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors.Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.Phosphoproteomics in translational research: a sarcoma perspective.Chemotherapy for soft tissue sarcoma.Newer medical therapies for metastatic soft tissue sarcoma.Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.

P2860

Q26746205-901F6FF6-A679-449D-8218-FFFF35F5B377 Q28081400-063E00F2-D3D3-42EC-972B-EB6D6C8196F1 Q28088685-C705281C-47F3-4CBE-9EA4-5BD532EAA230 Q30050175-BE1CE970-4E39-4182-80F9-B8A2B68A7DF5 Q30240228-5E45E931-08FC-4F10-BC1D-488E224BDD10 Q33276227-2731B4F4-628D-48C4-8F2B-FA19FD922A94 Q33430673-EDB6DAA3-1667-4AA7-B7EF-9B9AF386318C Q33558772-2467B9C2-6F5F-4C5B-AB2D-F2088DBD6EDA Q33598883-A5C29C33-BFA0-44AB-A87B-DE51A67A8DAF Q34045393-13D4FC1F-D1BB-4528-89CC-1A3C2E987D69 Q34554398-6EFCF67E-712C-42E9-AC3E-AE47F33FA153 Q34659806-23359697-5C04-4A58-A63C-9EC803F93DE7 Q34664479-DACF1657-1AE0-4495-BAA5-DD9138BAA985 Q34680171-90463DA5-AB30-47C2-AC7C-F8744AD68CEE Q34837681-62A75F10-38BB-4965-A493-155FE8130681 Q35118673-4856A491-CEC9-4807-8181-7E608E2D62BC Q35434188-BB531403-A167-4F29-8CDA-2B3B94A104B0 Q35767389-2FAD955B-A6FB-4997-ABD3-9D5D40FE8B5E Q35862728-06F7FAB6-4EF0-4EFE-8BA8-B58D348655C0 Q35935343-7469F7F2-125B-4F1F-9229-B32381FB08D0 Q36095476-E26D6D44-869D-42A2-B530-05D14830BFA2 Q36389964-3FA66A26-ACF7-4766-AA1B-1200041C5D81 Q36503259-2828752D-EAA6-4912-9B92-A159C6D298AE Q36717196-B349B8F0-CB75-48DB-A675-3C8C18DC6E69 Q37742014-BC2FB606-1455-4FC7-8748-9B289C57BD3E Q38165238-1143AA67-8E15-4B5C-8A3E-F633DA8A8E4F Q38197031-C365FADD-FE25-46EE-BEDB-EF9A60F50926 Q38226097-832F3B88-40E9-44C5-98AB-75D323E61F4C Q38232373-030D3EA1-6835-4637-BA0E-E48344C1BC7F Q38252537-FD0DF25D-05DF-4205-8039-2DD24FB2555C Q38378763-E7911A36-52CF-45A3-BB3A-DA8CDDDE74AB Q38563242-85D356E6-2380-4591-8B70-849E2B0884C4 Q38569799-C5B372E3-3109-4CD2-AD20-AAAC401D27A5 Q38591828-E7FC7505-773C-4661-9F85-D90523A73822 Q38654374-3EBD1F34-2344-4D8B-8576-96258C895699 Q38675589-730CA96B-CBD5-48BB-8719-8ED1B35A99CA Q38708614-27D866B3-C29C-4C9D-896F-AB5D1B9A2E2E Q38902113-F040400B-570B-4D35-BB47-9111E6E264ED Q39012067-5F0F92B0-6197-4522-B53D-41D9906EDD06 Q39204706-54210C12-0ECE-43D6-AEE3-D142D2E44559

P2860

Cediranib for metastatic alveolar soft part sarcoma

http://www.wikidata.org/entity/Q34651131

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Cediranib for metastatic alveolar soft part sarcoma

@ast

Cediranib for metastatic alveolar soft part sarcoma

@en

Cediranib for metastatic alveolar soft part sarcoma

@nl

type

label

Cediranib for metastatic alveolar soft part sarcoma

@ast

Cediranib for metastatic alveolar soft part sarcoma

@en

Cediranib for metastatic alveolar soft part sarcoma

@nl

prefLabel

Cediranib for metastatic alveolar soft part sarcoma

@ast

Cediranib for metastatic alveolar soft part sarcoma

@en

Cediranib for metastatic alveolar soft part sarcoma

@nl

P1433

Q34651131-94D19BE6-94C2-4DE2-93D5-AD6F1F881F8A

P1476

Q34651131-4B8AF8AA-43BE-4337-A08A-789C1A0A7216

P2093

Q34651131-018EB100-919F-424B-BCE7-35C2B50DCDB3

Q34651131-0EAE8A06-6C66-4296-9A8D-15796412D941

Q34651131-2303C731-C2D7-4FDE-8023-53B578A386B2

Q34651131-3BCA6D9A-C8AF-4F7F-92CF-B9DD12F9027E

Q34651131-62E39D70-D369-4993-A5C5-A7243A066EED

Q34651131-70219338-4C38-4932-9866-1B46B6EE857D

Q34651131-822B8337-BB73-4773-A6DE-5E8BE5F9369F

Q34651131-8972A7B6-3CA6-41D9-B969-15194BE1020A

Q34651131-8A5381F1-EA40-4D11-BF99-3711E2254147

Q34651131-8BB11CB1-AECB-45CF-B3E5-2A680B127F8F

P2860

Q34651131-01D325FC-D7F7-4B86-AAF7-2F372F951C23

Q34651131-1C15A160-A9AC-4E50-BD76-3844C04A9672

Q34651131-24A87357-A98B-42EF-93E3-D3E011E200A6

Q34651131-24F9E818-FE1D-4D74-A816-D61F38CFE840

Q34651131-260DB5CF-4268-4379-BDC6-B0380D413C11

Q34651131-28C3C4B1-D273-40E3-B3C2-FF17E8088063

Q34651131-329F0F82-47C5-404B-8B8B-9B6188299463

Q34651131-3C78AE45-6204-434D-B5DB-840E0481689C

Q34651131-3F7F1DDE-4DFE-459C-8B21-0AFA4862DA34

Q34651131-55AA0001-B599-4B0C-B368-7C7B42FF814F

P304

Q34651131-CD8F3389-3B42-4C29-A66C-0D1F4EA2519D

P31

Q34651131-80E968CB-E10E-4372-BC65-4B8A27FB8AA9

P356

Q34651131-88524E11-2F28-4D7F-B35F-50CFFF6A38AF

P407

Q34651131-D11D2348-A5AD-4406-B44A-DC543DF25288

P433

Q34651131-7B9AC6CE-0898-4779-887A-D09AC134B30E

P478

Q34651131-EA7CD9B3-6301-4134-BF81-7256839DBF77

P577

Q34651131-246B3E11-C3B6-4B85-8AB3-9B273E428D43

P698

Q34651131-F93D3A1B-2492-4A06-ABF8-FB9CD7DC1899

P932

Q34651131-4DCEF748-7187-4EAC-89A4-D2426901ADA5

P356

JCO.2012.47.4288

P1433

Journal of Clinical Oncology

P1476

Cediranib for metastatic alveolar soft part sarcoma

@en

P2093

Anne Monks

http://www.w3.org/2001/XMLSchema#string

Curtis D Hose

http://www.w3.org/2001/XMLSchema#string

Deborah Allen

http://www.w3.org/2001/XMLSchema#string

Eric C Polley

http://www.w3.org/2001/XMLSchema#string

Ismail B Turkbey

http://www.w3.org/2001/XMLSchema#string

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Lee Helman

http://www.w3.org/2001/XMLSchema#string

Peter Choyke

http://www.w3.org/2001/XMLSchema#string

Richard Simon

http://www.w3.org/2001/XMLSchema#string

Robert J Kinders

http://www.w3.org/2001/XMLSchema#string

P2860

Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target

Gene expression profiling of alveolar soft-part sarcoma (ASPS).

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.

Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution.

A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.

Chemotherapy in alveolar soft part sarcomas. What do we know?

P304

2296-2302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.47.4288

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23630200

http://www.w3.org/2001/XMLSchema#string

P932

3677840

http://www.w3.org/2001/XMLSchema#string